Advertisement


Emily L. Podany, MD, on Metastatic Breast Cancer: Racial Differences in Genomic Profiles and Targeted Treatment Use

2024 ASCO Annual Meeting

Advertisement

Emily L. Podany, MD, of Washington University, St. Louis, discusses disparities in the use of PI3K inhibitors for Black patients with estrogen receptor–positive, HER2-negative metastatic breast cancer while other drugs that do not require genomic profiling were similarly used (Abstract 1017). 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The study that I'm presenting is a multicenter consortium study. It consists of 1,327 patients that we looked at both genomic data through the liquid biopsy Guardant360 and clinical data that we got manually from the electronic medical record system. We decided to use this large multi-consortium database to ask questions about targeted treatment use in Black versus White patients. So we found that Black and White patients had equal incidence of PIK3CA mutations. But despite this equal incidence, they had differences in targeted treatment use. Black patients ended up having significantly less targeted treatment use than White patients in this dataset. Specifically, this was for these PI3 kinase inhibitor use. When we looked at mTOR inhibitor use and CDK4/6 inhibitor use, which does not require a specific finding in ctDNA or liquid biopsy, we actually didn't find any differences. So the only targeted treatment use differences was when there was a specific targeted finding in the ctDNA profiling. The other thing we looked at after that was we looked at overall survival in this cohort. We'd previously reported overall survival in the overall 1,327 patients, and then we looked specifically at HR-positive HER2-negative metastatic breast cancer patients, and we looked at ER positive, PR negative HER2 negative, and ER positive, PR positive HER2 negative. The PR-negative patients did significantly worse in terms of overall survival and Black patients with ER positive, PR negative HER2 negative did significantly worse than White patients with the same profile. Finally, we looked at clinical trial enrollment, so we looked at whether the patients with this PIK3CA mutation with metastatic breast cancer were enrolled in clinical trials at the same rate between Black and White patients. So we found that Black patients were significantly less likely to be enrolled in a clinical trial than White patients.

Related Videos

Breast Cancer

Pierfranco Conte, MD, on Early-Stage Triple-Negative Breast Cancer: Trial Update on Avelumab as Adjuvant Treatment

Pierfranco Conte, MD, of the University of Padua, discusses phase III findings from the A-BRAVE trial, which was designed to evaluate the efficacy of avelumab, an anti–PD-L1 antibody, as adjuvant treatment for patients with early-stage triple-negative breast cancer who are at high risk (LBA500).

Clifford A. Hudis, MD, and Karen E. Knudsen, MBA: An ASCO–American Cancer Society Partnership to Benefit Patients

Clifford A. Hudis, MD, CEO of the American Society of Clinical Oncology (ASCO), and Karen E. Knudsen, MBA, CEO of the American Cancer Society, discuss a newly launched collaboration between the organizations to make it simpler for patients to find authoritative cancer information online. The effort creates one of the largest and most comprehensive online resources for credible cancer information, available for free to the public on cancer.org.

 

Kidney Cancer

Toni K. Choueiri, MD, FASCO, on RCC: Biomarker Analysis From the CLEAR Trial

Toni K. Choueiri, MD, FASCO, of the Dana-Farber Cancer Institute, discusses phase III findings showing that, in patients with advanced renal cell carcinoma (RCC), the benefit of lenvatinib plus pembrolizumab vs sunitinib in overall response rate does not appear to be affected by such factors as geneexpression signatures for tumorinduced proliferation, PDL1 status, or the mutation status of RCC driver genes.

Prostate Cancer
Genomics/Genetics

Alicia Morgans, MD, MPH, and Susan Halabi, PhD, on Prostate Cancer: New Findings on Classifying Patients Into Risk Groups

Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Susan Halabi, PhD, of the Duke Cancer Institute and Duke University School of Medicine, discuss a clinical-genetic model that identified novel circulating tumor DNA alterations that are prognostic of overall survival and may help to classify patients with metastatic castration-resistant prostate cancer into risk groups useful for selecting trial participants (Abstract 5007).

Breast Cancer

Sherene Loi, MD, PhD, on Early-Stage Breast Cancer: Weighing the Prognostic Value of ctDNA Detection

Sherene Loi, MD, PhD, of Peter MacCallum Cancer Centre, discusses a circulating tumor DNA (ctDNA) analysis from a cohort of patients with early-stage breast cancer who were enrolled in the monarchE trial. This large cohort was studied to look at the usefulness of a personalized tumor-informed assay for ctDNA detection in early stage high-risk patients (LBA507).

Advertisement

Advertisement




Advertisement